A Randomised, Double-blind (Sponsor Open), Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 in Healthy Male Participants
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2018
At a glance
- Drugs GSK-3358699 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 30 Aug 2018 The treatment table has been amended to include one more arm: Part B, GSK3358699 under Fasted followed by Fed conditions. The dosage of GSK3358699 capsule has been changed to 3-45mg.
- 30 Aug 2018 Planned primary completion date changed from 30 May 2019 to 29 Jul 2019.